Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3979171 | Bulletin du Cancer | 2011 | 6 Pages |
Abstract
The extent of cytoreductive surgery and the amount of residual disease are among the most important factors impacting the survival of women with advanced ovarian cancer. Chronology of treatment is still debating. In the French standard treatment, primary surgery remains the cornerstone and interval surgery is an option. Neoadjuvant chemotherapy followed by surgery may reduce morbidity and mortality. Nevertheless the impact of this strategy on survival is still controversial.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Isabelle Jaffré, Virginie Bordes, Magali Dejode, François Dravet, Jean-Sébastien Frénel, Dominique Berton-Rigaud, Jean-Marc Classe,